Advertisements

Flexium (Etofenamate)

Quick links to important sections

Flexium (Etofenamate)

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Flexium (Etofenamate)

Property Description
Active Ingredient Etofenamate (INN)
Primary Form Topical (Gel, Cream, Spray)
Pharmacological Class Non-steroidal Anti-inflammatory Drug (NSAID)
Core Function Anti-inflammatory and Analgesic
Origin Synthetic Prodrug (Glycol Ester)

Flexium is a trade name for the medication containing the active ingredient Etofenamate, a drug primarily used to target localized pain and inflammation. The substance is a single-ingredient product known internationally by its non-proprietary name, Etofenamate, which reflects its consistent chemical identity. The topical formulations of Etofenamate are used for providing relief in typical scenarios of musculoskeletal discomfort.


What Type of Medicine is Etofenamate (Flexium)?

Etofenamate is classified as a Non-steroidal Anti-inflammatory Drug (NSAID), belonging to the chemical subgroup of anthranilic acid derivatives.

The compound is synthetic, defined chemically as a glycol ester derivative of flufenamic acid. This structure establishes Etofenamate as a prodrug; it is designed to be absorbed and subsequently metabolized into the active component, flufenamic acid, to initiate its pharmacological effects. The NSAID classification defines its role in modulating the body’s inflammatory response and reducing associated pain signals.


Etofenamate Composition and Available Forms

Etofenamate is an active ingredient frequently prepared for topical/cutaneous delivery, a method that aims to concentrate the substance locally while minimizing systemic exposure, a distinguishing feature from oral NSAIDs.

The medication is offered in several physical forms for localized use, predominantly including gel, cream, spray, and lotion. These formulations typically utilize an alcohol-based emulsion to aid the active substance's passage through the skin barrier. Etofenamate is also produced as an oily solution for intramuscular (IM) injection, providing an alternative systemic route of administration.


General Purpose of Etofenamate (Flexium)

The fundamental purpose of Etofenamate is to deliver both anti-inflammatory and analgesic effects directly to the area of discomfort.

This dual capability is rooted in its action as a cyclooxygenase (COX) inhibitor. The general benefit of Etofenamate is to target the sensation of pain and the underlying condition of swelling, making it suitable for a typical use scenario such as alleviating discomfort from localized stiffness following physical activity or minor strains. The drug is utilized in managing these general musculoskeletal aches.

Advertisements

What side effects are possible with Flexium (Etofenamate)?

Possible Side Effects and Safety Information

The official safety profile for topical etofenamate, a Non-steroidal Anti-inflammatory Drug (NSAID), is structured around adverse reactions documented in clinical use and specific safety constraints defined by government regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are primarily associated with the application site due to the topical route. The classification of frequency follows regulatory standards:

  • Rare (ge 1/10,000 to <1/1000): Local irritation of the skin, which may include allergic eczema, a general allergic rash, contact dermatitis, or a weeping rash.
  • Very Rare (<1/10,000): Severe Cutaneous Adverse Reactions (SCARs).

The most commonly documented adverse events fall under Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Safety Patterns

Serious Reactions: The official label documents the Very Rare possibility of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. These are risks associated with the NSAID class generally.

Time Pattern: The risk of these Severe Cutaneous Adverse Reactions is noted in regulatory sources to be greatest at the beginning of treatment, with most cases manifesting within the first month.

Population-Specific Safety Restrictions

Use of etofenamate is officially not recommended in children and infants or during pregnancy and lactation, due to the unestablished safety profile of the absorbed substance in these groups. Regulatory studies have not indicated a need to change the recommended dosage for patients with impaired renal function.

Application Constraints

The medicine is officially contraindicated in individuals who are hypersensitive to etofenamate or other NSAIDs, including aspirin. Application is prohibited on broken skin, open wounds, ulcerated areas, or damaged skin. Additionally, the application site must avoid sun exposure due to the documented risk of contact photosensitivity.

This framework defines the medicine’s official risk characteristics, separating common local effects from very rare, serious, class-related risks.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Etofenamate (Flexium) overdose is determined by its topical route of administration, which results in low systemic absorption. For the most common cutaneous formulations, government labeling explicitly indicates that overdosage is not considered a practical possibility under intended use. This low-risk assessment is further supported by the regulatory confirmation that no cases of overdose have been reported for the topical formulation.

Overdose Profile Summary

Regulatory Statement Overdose Classification
Overdosage is not considered a practical possibility Negligible Severity (Under intended use)
No cases of overdose have been reported Based on topical route constraint

Documented Manifestations and Actions

Because of the low systemic risk, specific clinical manifestations such as central nervous system effects, gastrointestinal symptoms, or organ function deterioration are not listed in the official overdose section for the topical product. The labeling, therefore, does not mandate specific emergency actions. However, should accidental oral ingestion or excessive systemic exposure occur, a healthcare professional must be contacted immediately for evaluation. Management, if required for symptomatic exposure, is defined by regulatory bodies as symptom-focused and supportive, consistent with general non-steroidal anti-inflammatory drug (NSAID) protocol. No specific antidote for Etofenamate overdose is described in the official product labeling.

Advertisements

Therapeutic Uses of Flexium (Etofenamate)

Etofenamate is commonly used in situations involving certain distressing symptoms associated with musculoskeletal issues. It is applied in contexts where additional symptomatic support is needed to help patients cope more steadily with difficult episodes of discomfort. The medication is considered relevant across a range of traumatic and rheumatic presentations.


Symptom Management and Key Indications

This medication is considered relevant for easing symptoms related to localized pain, tenderness, swelling, and functional stiffness. It is generally applied in addressing conditions characterized by episodic or recurrent symptom patterns, including mild to moderate muscle pains, contusions, ligament sprains, bursitis, tendinitis, and localized joint discomfort in conditions like osteoarthritis. The topical application assists with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened symptoms.

“It is relevant for managing symptoms that interfere with daily comfort.”


Quick Fact and Therapeutic Focus

Etofenamate is generally applied in settings where short-term symptomatic assistance is needed, such as during phases when localized pain or inflammation become more noticeable. It supports patients during episodes of heightened discomfort related to soft tissue injuries and regional pain syndromes.

Quick Fact: Relief for Localized Pain and Inflammatory Symptoms

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Flexium (Etofenamate)?

Regulatory documents define specific populations who should not use Flexium (Etofenamate) and groups for whom use is not recommended due to a lack of data.


Formal Contraindications (Must Not Use)

Flexium is formally contraindicated for patients who have:

  • Hypersensitivity to etofenamate or any of its excipients.
  • Hypersensitivity to other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin, due to the risk of cross-reaction.
  • For topical formulations, application is contraindicated on eczematous surfaces, open wounds, areas with ulcers, or injured or damaged skin.

Eligibility Restrictions (Not Recommended Use)

Use is not recommended for the following populations or conditions, typically due to insufficient studies or established safety concerns:

Population / State Eligibility Status (Regulatory)
Children and Infants Not Recommended (Lack of specific studies)
Pregnancy Contraindicated/Not Recommended
Lactation/Breastfeeding Not Recommended
Peptic Ulcer (for certain forms) Contraindicated
Hepatic or Renal Impairment No specific dose adjustment indicated, but caution is advised as no specific studies were conducted in these populations.

Adults who do not have any of the listed contraindications or restrictions are the general eligible population. The regulatory profile heavily restricts use based on a history of NSAID sensitivity, the condition of the skin at the application site, and the absence of established safety data for pediatric or reproductive health groups.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flexium (Etofenamate) is a non-steroidal anti-inflammatory drug (NSAID) and its interaction profile requires caution, primarily due to the risk of systemic absorption, which mirrors the effects of oral NSAIDs.

Documented Interaction Categories and Constraints

Category Practical Regulatory Constraint (Risk)
Other NSAIDs (Topical or Systemic) Avoidance of co-administration due to increased risk of adverse effects.
Oral Anticoagulants (e.g., Coumarin derivatives) Close monitoring of coagulation status is required due to an increased risk of bleeding.
Corticosteroids and Antiplatelet Agents Increased risk of bleeding. Close monitoring is necessary.
Methotrexate (at high doses) May lead to elevated serum levels and increased toxicity of methotrexate due to its decreased renal elimination.

Interaction Structure Summary

Official regulatory information emphasizes that the concurrent use of etofenamate with other Non-Steroidal Anti-Inflammatory Drugs, regardless of their route of administration (topical or systemic), should be avoided. The primary documented mechanistic concern is the potential for pharmacodynamic synergy resulting in a heightened risk of bleeding when etofenamate is combined with anticoagulant medications, corticosteroids, or other antiplatelet agents. The combination with high-dose methotrexate carries a risk of pharmacokinetic interaction where etofenamate may reduce the elimination of methotrexate, necessitating strict caution and monitoring when these medicines are used together.

Advertisements

Mechanism of Action

The mechanism of Etofenamate is achieved through its conversion from the inactive parent molecule into the pharmacologically active metabolite, flufenamic acid, which modulates two core physiological pathways at the site of administration.

Prodrug Activation and Cyclooxygenase Inhibition

The parent ester molecule undergoes rapid hydrolysis within the tissue to yield the active compound, flufenamic acid. This metabolite acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, primarily targeting the COX-2 isoform. This inhibition prevents the initial step in the formation of prostaglandins and other eicosanoids, which are key chemical mediators that influence the localized inflammatory cascade. This action modifies the biochemical signals that drive inflammatory processes.

Modulation of Local Nociceptive Signaling

Beyond blocking prostaglandin synthesis, the active metabolite influences the activity of specific ion channels within peripheral cell membranes. This mechanism contributes to the drug's effect profile by stabilizing nerve endings and reducing the excitability of local nerve structures. This combined action constrains both the chemical amplification of the inflammatory cascade and the electrical generation of pain signals, resulting in a dampening of the peripheral nociceptive signal.

Advertisements

Dosage and Administration Information

Etofenamate is administered via two routes: topical application (gel or cream) for localized relief and intramuscular (IM) injection for limited systemic use. The topical formulation is available in concentrations such as 5% w/w and 10% w/w gels.


Administration Protocol

The standard regimen for the topical gel involves applying a measured amount to the affected area. For the 5% gel, this is typically a 5–10 cm strip per dose, while the 10% gel involves a 2.5–5 cm strip. This dose is applied up to 4 times daily and is gently rubbed in to facilitate absorption. After applying, hands are thoroughly washed, unless the hands are the site being treated.

Topical use involves specific duration constraints. Treatment is reviewed after 14 days for soft tissue injuries and 4 weeks for symptomatic osteoarthritis. The total course of treatment generally does not extend beyond 6 weeks. The intramuscular injection is reserved for single-dose administration of 1 g (one ampoule), often used at the initiation of treatment.


Population-Specific Usage

Regarding patient groups, the topical formulation is not recommended for use in children or infants. For older adults and patients with renal or hepatic impairment, prescribing information for topical Etofenamate does not indicate a need for dose adjustment from the standard adult regimen. The application is restricted from broken or irritated skin and mucous membranes.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flexium (Etofenamate)

Evidence for Use in Acute Soft Tissue Injuries

The research on Etofenamate for acute problems like sprains, strains, and contusions was studied for short, defined time periods using Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms in adults. Outcomes tracked outcomes related to physical discomfort, such as pain intensity and changes in localized swelling. Trials describe patterns observed in the changes in discomfort over the typical 7- to 14-day study period. The research provides context but not individual predictions for outcomes beyond the short term, and comparative evidence is lacking against the most recently developed topical pain relief options.

Evidence for Use in Localized Joint Pain in Osteoarthritis

Etofenamate was evaluated in research involving localized joint pain related to mild to moderate Osteoarthritis. The research explores short-term symptom changes using the topical gel/cream as well as the intramuscular (IM) injection. This research examines patient-reported outcomes describing perceived discomfort and functional status using measures like the WOMAC Index. Trials documented measurements of functional status and pain over periods that ranged from a few weeks (topical) to up to 12 months (IM injection). The research is heterogeneous due to differing administration routes, and limited information for long-term outcomes is available specifically for the topical form.

Evidence for Use in Soft Tissue Rheumatic Conditions

For conditions such as lumbago, tendinitis, and bursitis, Etofenamate was studied for its application in conditions involving periods of heightened symptoms using Controlled Double-Blind Trials and systematic reviews. The studies monitored outcomes related to systemic or functional imbalance, tracking changes in pain intensity and assessing the observed changes in localized inflammatory symptoms. A key limitation is that much of the evidence is based on a substantial proportion of older comparative studies, and the follow-up durations were limited, typically restricted to 7 to 15 days.

Extended Observation Periods and Long-Term Data

Research conducted to date has largely focused on shorter observation windows. While some IM injection investigations have monitored responses over defined time intervals extending up to a year, the majority of the research for the topical formulation does not extend beyond a few weeks. Because of this, long-term effects are not fully established for the typical topical use.

Evidence in Special Populations

The research has predominantly been conducted on general adult populations, meaning data for certain groups remain insufficient. There is limited information available from studies that have examined patient-reported experiences in distinct populations, such as children, pregnant individuals, or very older adults. The research does not determine whether an individual with pre-existing comorbidities was observed to fit the patterns described in the broader study populations.

What Remains Uncertain About Flexium (Etofenamate) Research

Current evidence highlights what is known — and what is still uncertain. A primary limitation is the volume of available research against competitor products; comparative evidence is lacking in this modern context. Furthermore, as many trials were short in duration, the follow-up durations were limited, and overall, evidence quality varies across studies.

Key Studies & References

  1. Summary of Product Characteristics: Flexium (Etofenamate)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Flexium (Etofenamate) (FAQ)


Q: Is Flexium the same type of medicine as ibuprofen or naproxen?

Flexium (Etofenamate) belongs to the same general drug class as ibuprofen and naproxen, which is the Non-Steroidal Anti-inflammatory Drugs (NSAIDs). However, Etofenamate is chemically defined as an anthranilic acid derivative and a prodrug of flufenamic acid, which places it in a different chemical sub-group compared to the other two medicines.


Q: What is the main difference between Flexium gel and the tablet form, if there is one?

The key difference is the route of administration and the amount of medicine absorbed by the body. The topical gel is designed for relief with a localized action at the application site, resulting in minimal and slow systemic absorption. This contrasts with oral tablet forms of NSAIDs, which are intended to have a more immediate systemic effect throughout the body.


Q: Does Flexium help with nerve pain or is it only for muscle aches?

Official information describes Etofenamate's function as both anti-inflammatory and analgesic (pain relief). Its mechanism of action involves modulating the inflammatory process and is described as influencing both the inflammatory cascade and the generation of pain signals in the periphery.


Q: Can I use Flexium if I have sensitive skin?

Localized skin reactions, such as skin irritation, allergic eczema, and contact dermatitis (a type of rash), are listed as possible side effects in official product information. Official information notes that the product is formally contraindicated for application on skin that is broken, damaged, or eczematous.


Q: Can Flexium be used for pain in the feet or ankles?

The medicine is indicated for treating pain, inflammation, and stiffness associated with soft tissue injuries (e.g., sprains) and for localized joint pain (e.g., mild osteoarthritis). Since these conditions commonly affect areas like the feet and ankles, official documentation describes the medicine as indicated for application to these affected joints and muscles.


Q: Does Flexium interact with common high blood pressure medications?

Official documentation requires that caution be exercised when Flexium is used alongside medicines that may interact with NSAIDs. While specific high blood pressure medicines are not universally listed, NSAIDs are known to carry a potential for interaction with medicines like diuretics and antihypertensives due to a class effect. The potential for interaction and the need for monitoring are considerations for healthcare providers when these medicines are used concurrently.


Q: Can I use Flexium if I am taking an aspirin regimen?

Official documents describe an increased risk of bleeding when Etofenamate is used concurrently with antiplatelet agents, such as an aspirin regimen. Because of this risk, this combination requires close medical monitoring by a healthcare provider.


Q: Can using Flexium for a long time affect my stomach, even though it's a cream/gel?

Since the topical gel is designed for localized action, it provides minimal systemic absorption of the active substance. This reduced absorption generally results in a lower risk of the gastrointestinal side effects that are often associated with taking oral NSAIDs.


Q: What are the signs that a side effect from Flexium is serious?

Official warnings note the very rare possibility of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome. Official warnings describe signs such as any sudden and widespread serious skin reactions, the development of fever, blisters, or a spreading rash, as risks associated with the NSAID class generally.


Q: Does Flexium make you drowsy or affect your ability to drive?

Official product information states that based on the topical route of administration, the medicine is not documented to have an effect on a patient’s ability to drive or operate machinery.


Q: Is Flexium approved for use in children?

Official product information states that the use of Etofenamate topical gel is not recommended for children or infants. This is due to the lack of established safety and efficacy data for the absorbed substance in these younger age groups.


Q: Can Flexium be used to relieve muscle soreness after exercise?

The medicine is officially indicated for the treatment of pain and inflammation. The official indications apply to the treatment of soft tissue injuries, such as strains and contusions, which may occur during sports or physical activity.


Q: Is it safe to use Flexium while sunbathing or using a tanning bed?

The official product information notes that the application site must avoid sun exposure, including tanning lamps. This is due to the documented risk of contact photosensitivity (increased skin sensitivity to light) associated with the medicine.


Q: Does Flexium have an effect on healing time, or just on pain?

Flexium is a Non-Steroidal Anti-inflammatory Drug (NSAID) whose primary function is to provide symptomatic relief. Its documented effects are specifically focused on providing anti-inflammatory and analgesic effects (reducing pain and inflammation), rather than having an effect on the time it takes for a tissue injury to heal.


Q: Is the smell of Flexium important to its function?

The odor associated with the product is generally due to the presence of excipients (inactive ingredients) in the formulation. Components like alcohols or fragrances are often included to act as solvents or to help the active substance, Etofenamate, pass through the skin barrier more effectively.


Q: Is Flexium considered addictive in any way?

The medicine is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID) that acts locally at the site of inflammation. NSAIDs do not contain components that are classified as narcotic or controlled substances, and they do not have the potential for dependence.


Q: Can I take other pain relievers while using topical Flexium?

Official information emphasizes the need for avoidance of co-administration with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), whether they are topical or taken orally. This is a critical constraint aimed at reducing the risk of adverse effects.


Q: What should I do if a child accidentally touches the Flexium gel?

Official product information emphasizes that the medicine must be kept out of the reach of children and stored securely. In the event of accidental exposure or ingestion, regulatory authorities indicate that emergency medical attention or contact with a poison control center may be warranted.


Q: Why is alcohol sometimes listed as an ingredient in topical Flexium products?

Alcohol, such as ethanol, is often included as an excipient (inactive ingredient) in the topical formulation. Its role is typically to act as a solvent or a cutaneous penetration enhancer, which helps the active ingredient move through the skin barrier to the underlying tissue.


Q: Is it common to get a rash where the Flexium was applied?

Local skin irritation, which may include allergic eczema, contact dermatitis, or a rash, is listed in the official safety profile as a rare adverse reaction. This means it occurs infrequently (in ge 1/10,000 to <1/1000 patients) during normal clinical use.


Q: What does the term 'localized pain relief' mean in the context of Flexium?

This term means that the medicine is formulated to act primarily at the site of application on the skin. It aims to deliver a high concentration of the active substance to the underlying tissue to target pain and inflammation only in that specific area, rather than having a full-body systemic effect.


Q: Is it safe to use Flexium for long periods of time, like several months?

The official protocol advises specific constraints on the duration of use. Treatment should be reviewed after 14 days for soft tissue injuries and 4 weeks for symptomatic osteoarthritis, and generally should not be extended beyond 6 weeks for the topical formulation.

Advertisements

How should Flexium (Etofenamate) be stored and disposed of?

Storage and Disposal of Flexium (Etofenamate) Gel

The storage and disposal instructions for Flexium gel are defined by regulatory documents to maintain product stability and ensure safety.

Requirement Area Official Regulatory Wording
Temperature & Light No special temperature storage conditions required; store in the original package for protection from light (HPRA SmPC).
Packaging & Handling Keep the container tightly closed and store the product in the original package (SDS; HPRA SmPC).
Stability after Opening Must be used within a maximum period of 6 months after the tube is first opened (HPRA SmPC).
Child Safety Must be kept out of the reach of children and stored locked up (SDS).
Disposal Instructions Dispose of contents and container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations (SDS). Release to the environment must be avoided (SDS).

This information describes the mandated environmental conditions, container integrity rules, and the limited post-opening stability period, along with required environmental and child-safety handling procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flexium (Etofenamate) found in:

A-Z Index: